GreenLight Biosciences, a Medford, Mass.-based developer of a cell-free approach to microbial chemical production, raised a Series C round of funding.
The amount of the deal remained undisclosed.
The round was led by MLS Capital Fund II, co-managed by Spruce Capital Partners and Xeraya Capital, with participation from both new and existing investors.
Led by Andrey Zarur, Ph.D. Co-Founder, CEO, and Chairman, GreenLight is a developer of a cell-free approach to microbial chemical production, enabling a clean bio-based manufacturing platform to produce chemicals from renewable, non-petroleum based resources.